(NASDAQ: MOR) Morphosys Ag's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.15%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.02%.
Morphosys Ag's revenue in 2023 is N/A.On average, 2 Wall Street analysts forecast MOR's revenue for 2023 to be $13,011,787,573, with the lowest MOR revenue forecast at $12,439,865,262, and the highest MOR revenue forecast at $13,583,709,883. On average, 2 Wall Street analysts forecast MOR's revenue for 2024 to be $16,526,659,173, with the lowest MOR revenue forecast at $15,414,066,204, and the highest MOR revenue forecast at $17,639,252,141.
In 2025, MOR is forecast to generate $31,022,131,735 in revenue, with the lowest revenue forecast at $31,022,131,735 and the highest revenue forecast at $31,022,131,735.